<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001873032</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.01</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>12/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001380106</issuerCik>
        <issuerName>Rapid Micro Biosystems, Inc.</issuerName>
        <issuerCusip>75340L104</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">25 Hartwell Avenue</street1>
          <city xmlns="http://www.sec.gov/edgar/common">Lexington</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">02421</zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Endeavour Medtech Growth II LP</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>Y7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2257099</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2257099</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2257099</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.7</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>
(1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(2) Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025 (the "Form 10-Q").</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Endeavour Medtech Growth II Parallel LP</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>Y7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2257099</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2257099</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2257099</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.7</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>
(1) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(2)  Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Endeavour Medtech II GP Limited</reportingPersonName>
      <memberGroup>b</memberGroup>
      <citizenshipOrOrganization>Y7</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>2257099</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>2257099</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>2257099</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>5.7</classPercent>
      <typeOfReportingPerson>PN</typeOfReportingPerson>
      <comments>
(3) Includes (i) 2,217,190 shares of Class A common stock held by Endeavour Medtech Growth II LP and (ii) 39,909 shares of Class A common stock held by Endeavour Medtech Growth II Parallel LP.
(4)  Based on 39,823,026 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2025 as reported by the Issuer in the Form 10-Q, filed with the United States Securities and Exchange Commission (the "Commission") on November 7, 2025.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Rapid Micro Biosystems, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>25 Hartwell Avenue, Lexington, MA 02421</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>This Statement is filed on behalf of each of the following persons (collectively, the "Reporting Persons"):


 (i) Endeavour Medtech Growth II LP
(ii) Endeavour Medtech Growth II Parallel LP
(iii) Endeavour Medtech II GP Limited</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>The address of the principal business and principal office of each of the Reporting Persons is P.O. Box 656, East Wing Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3PP</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Each of (1) Endeavour Medtech Growth II LP, (2) Endeavour Medtech Growth II Parallel LP and (3) Endeavour Medtech II GP Limited is a Guernsey limited partnership.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Endeavour Medtech Growth II LP

2,217,190 shares of Class A common stock are held of record by Endeavour Medtech Growth II LP ("EMG II"). Endeavour Medtech II GP Limited ("Endeavour GP") is the general partner of EMG II.

Endeavour Medtech Growth II Parallel LP

39,909 shares of Class A common stock are held of record by Endeavour Medtech Growth II Parallel LP ("EMG II AFF"). Endeavour GP is the general partner of EMG II AFF.

As a result of foregoing, and the relationships described in Item 2(a) of this Schedule 13G, the Reporting Persons may be deemed to share ownership over the reported 2,257,099 shares of Class A common stock, but the filing of this Statement shall not be deemed an admission of such beneficial ownership by any of the Reporting Persons for purposes of Section 13(d) or Section 13(g) or for any other purpose.</amountBeneficiallyOwned>
        <classPercent>5.7%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>2,257,099</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>2,257,099</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>N</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Endeavour Medtech Growth II LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nick Barton</signature>
        <title>Nick Barton, Director</title>
        <date>02/13/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Endeavour Medtech Growth II Parallel LP</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nick Barton</signature>
        <title>Nick Barton, Director</title>
        <date>02/13/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Endeavour Medtech II GP Limited</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Nick Barton</signature>
        <title>Nick Barton, Director</title>
        <date>02/13/2026</date>
      </signatureDetails>
    </signatureInformation>
    <signatureComments>
Endeavour Medtech Growth II LP is signed for by Endeavour Medtech II GP Limited, its General Partner.
Endeavour Medtech Growth II Parallel LP is signed for by Endeavour Medtech II GP Limited, its General Partner..</signatureComments>
  </formData>
</edgarSubmission>
